

# According to Dr. Anthony Fauci the Reopening of the US Economy Would Endanger People's Health

15 Years Ago Chloroquine Was Recommended by the CDC as "A potent inhibitor of SARS Coronavirus". Why is Fauci Blocking It?

By [Prof Michel Chossudovsky](#)  
Global Research, May 23, 2020

Region: [USA](#)  
Theme: [Science and Medicine](#)

**Anthony Fauci**, director of the IHSS is playing a "blame game".

*He wants the lockdown to continue, no reopening of the US economy because that would endanger people's health.*

*Dr. Fauci intimates that hydroxychloroquine and chloroquine are dangerous. The evidence is anecdotal, says Fauci. The corporate media presents it as a untested drug.*

"The only tool we have right now for fighting the coronavirus is social distancing" says Dr. Fauci. And of course confinement, "stay at home". Neither of these "recommendations" are medical solutions, i.e. drugs which can be used to prevent and inhibit the infection.

Fauci is opposed to the treatment of COVID-19 using chloroquine. What he wants is for all of us to be vaccinated.

According to [CNN](#), Trump is to blame:

Trump has been pressing federal health officials to make the drugs — hydroxychloroquine and chloroquine — more widely available, **despite little reliable evidence that they are effective** at treating the virus. (emphasis added)

# Fauci throws cold water on Trump's declaration that malaria drug chloroquine is a 'game changer'

*Fauci says chloroquine hasn't been studied on coronavirus.*

By [Anne Flaherty](#) and [Jordyn Phelps](#)

20 March 2020 17:22 · 7 min read



“Fauci says chloroquine has not been studied on coronavirus”.

What Fauci fails to mention is that Chloroquine was “studied” and tested fifteen years ago by the CDC as a drug to be used against coronavirus infections.

According to the [NYT](#),

The federal agency led by Dr. Anthony Fauci issued guidelines on [April 21] that **stated there is no proven drug for treating coronavirus patients** (emphasis added)

The report echoed what frustrated doctors already know: Not enough is known about the highly infectious virus or how to combat it.

**“No proven drug”: “Not Enough Known”**. Nonsensical and irresponsible statements.

Chloroquine was used in 2002 and tested against SARS-1 coronavirus in a study under the auspices of the CDC published in the *Virology Journal*.

An August 2005 report in the peer reviewed *Virology Journal* (summary below) was published in 2005.

The main conclusion of the article was that: ***Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.*** It was used in the SARS-1 outbreak in 2002. It had the endorsement of the CDC.



Research | [Open Access](#) | Published: 22 August 2005

## Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

[Martin J Vincent](#), [Eric Bergeron](#), [Suzanne Benjannet](#), [Bobbie R Erickson](#), [Pierre E Rollin](#), [Thomas G Ksiazek](#), [Nabil G Seidah](#) & [Stuart T Nichol](#) [✉](#)

[Virology Journal](#) **2**, Article number: 69 (2005) | [Cite this article](#)

**264k** Accesses | **176** Citations | **27548** Altmetric | [Metrics](#)

### Abstract

#### Background

Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.

#### Results

We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of

\*\*\*

[Martin J Vincent](#), [Eric Bergeron](#), [Suzanne Benjannet](#), [Bobbie R Erickson](#),

[Pierre E Rollin](#), [Thomas G Ksiazek](#), [Nabil G Seidah](#) & [Stuart T Nichol](#)

[Virology Journal](#) **volume 2**, Article number: 69 (2005)

Scroll down for excerpts of the article in the Virology Journal published by BioMed Central. [Access to the complete article.](#)

The main author Dr. **Martin J. Vincent** together with several of his colleagues were affiliated with the Special Pathogens Branch of the Atlanta based CDC together with co-authors from a Montreal based partner research institution. The main conclusions of this study are that Chloroquine is a tested drug and can be used for SARS-corona virus infections:

“Preinfection chloroquine treatment renders Vero E6 cells refractory to SARS-CoV infection”

“Postinfection chloroquine treatment is effective in preventing the spread of SARS-CoV infection”

Dr. Anthony Fauci is not proposing a treatment which can be applied against COVID-19. What he is saying is that there is no treatment.

What he is doing is blocking a drug which had been endorsed by the CDC 15 years ago for treatment of SARS-1 Coronavirus. More recently, it has been used extensively in a number of countries in relation to the **SARS-2 Coronavirus or SARS-COV2 (COVID-19)** outbreak. The impacts of these treatments are subject to controversy, with systematic attempts to disparage the use of chloroquine.

It was also endorsed by several Chinese virologists. (See below). A peer reviewed report in [The Lancet](#) confirms the use of chloroquine and hydroxychloroquine in China:

The drug was rapidly pushed to clinical testing as an experimental treatment in China; on Feb 15, 2020, it was included in the sixth version of the COVID-19 treatment guidelines by the National Health Commission of the People’s Republic of China. This guideline established the use of chloroquine nationwide for patients with COVID-19, at a recommended adult dose of 500 mg twice per day for no more than 10 days. [1](#)

Dr. Antony Fauci has not put forth a preventive or effective treatment of the COVID-19. Fauci’s statement to the effect that there is no cure for COVID-19 borders on ridicule. COVID-19 is a corona virus which triggers pneumonia and respiratory tract infections, for which there are several known cures.

For those who are sceptical, read **Dr. Anthony Fauci’s** peer reviewed article on SARS-COV2 together with co-authors **Clifford Lane** and CDC Director **Robert Redfield** published on February 28, 2020 in [The New England Journal of Medicine](#).

*According to the WHO, “The most commonly reported symptoms [COV-19] included fever, dry cough, and shortness of breath, and **most patients (80%) experienced mild illness.**”*

Dr. Fauci broadly acknowledges and explains the WHO definition of COVID in his peer reviewed NEJM article. His media hype statements however are “misleading”.

**The World Health Organization says those who become infected generally experience mild illness and recover in about two weeks.**

**And Here is the Hype of Dr. Fauci:**

---

# Fauci warns coronavirus could kill as many as 200,000 Americans

**Top US infectious disease expert cautions that figure is a 'moving target' that could easily be wrong**

- [Coronavirus - live US updates](#)
- [Live global updates](#)
- [See all our coronavirus coverage](#)



The Hill

## The Vaccine

Dr. Fauci is currently pushing for the development of a multibillion dollar vaccine on behalf of Big Pharma and the Gates Foundation. He is in conflict of interest. And that vaccine is far more dangerous than chloroquine.

\*\*\*

## ANNEX

For further details on the current SARS-2 coronavirus (alias COVID-19) as well as its relationship to SARS-1 coronavirus, see the peer reviewed article by **Anthony Fauci** and co-authors **Clifford Lane** and CDC Director **Robert Redfield** published in March issue of [The New England Journal of Medicine](#)

**Excerpt from the VJ article entitled**

**Chloroquine is A potent inhibitor of SARS Coronavirus Infection and Spread**

[Martin J Vincent](#), [Eric Bergeron](#), [Suzanne Benjannet](#), [Bobbie R Erickson](#), [Pierre E Rollin](#), [Thomas G Ksiazek](#), [Nabil G Seidah](#) & [Stuart T Nichol](#)

## Results

We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.

## Conclusion

Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.

[Read more here \(complete article\)](#)

## Reviews

[Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus \(2019-nCoV\) in vitro](#)

M Wang, R Cao, L Zhang, [X Yang](#), J Liu, M Xu, Z Shi... - Cell research, 2020 - nature.com

In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China. The initial cases were linked to exposures in a seafood market in Wuhan. 1 As of January 27, 2020, the Chinese authorities ...

[Cited by 1137 All 8 versions](#)

[\[PDF\] oup.com](#)

[In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 \(SARS ...](#)

X Yao, F Ye, M Zhang, C Cui, B Huang... - Clinical Infectious ..., 2020 - academic.oup.com

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of ...

# In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Xueting Yao, Fei Ye, Miao Zhang, Cheng Cui, Baoying Huang, Peihua Niu, Xu Liu, Li Zhao, Erdan Dong, Chunli Song ... [Show more](#)

[Author Notes](#)

*Clinical Infectious Diseases*, ciaa237, <https://doi.org/10.1093/cid/ciaa237>

**Published:** 09 March 2020 **Article history** ▼

 PDF  Split View  Cite  Permissions  Share ▼

## Abstract

### Background

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.

### Methods

The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2-infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile.

The original source of this article is Global Research  
Copyright © [Prof Michel Chossudovsky](#), Global Research, 2020

[Comment on Global Research Articles on our Facebook page](#)

Articles by: **[Prof Michel Chossudovsky](#)**

### **About the author:**

Michel Chossudovsky is an award-winning author, Professor of Economics (emeritus) at the University of Ottawa, Founder and Director of the Centre for Research on Globalization (CRG), Montreal, Editor of Global Research. He has undertaken field research in Latin America, Asia, the Middle East, sub-Saharan Africa and the Pacific and has written extensively on the economies of developing countries with a focus on poverty and social inequality. He has also undertaken research in Health Economics (UN Economic Commission for Latin America and the Caribbean (ECLAC), UNFPA, CIDA, WHO, Government of Venezuela, John Hopkins International Journal of Health Services (1979, 1983) He is the author of 13 books including The Globalization of Poverty and The New World Order (2003), America's "War on Terrorism" (2005), The Globalization of War, America's Long War against Humanity (2015). He is a contributor to the Encyclopaedia Britannica. His writings have been published in more than twenty languages. In 2014, he was awarded the Gold Medal for Merit of the Republic of Serbia for his writings on NATO's war of aggression against Yugoslavia. He can be reached at [crgeditor@yahoo.com](mailto:crgeditor@yahoo.com)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)